Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Last trade$27.31
Day change+$0.16 (+0.59%)
Day range$26.47 – $27.65
Volume594,698
Market cap$3.43B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.43B
Price / earnings
114.79×
Price / book
14.07×
Price / sales
6.75×
EV / sales
6.9×
EV / EBITDA
107.17×
Profitability
Earnings per share
$0.24
Return on assets
5.7%
Return on equity
12.26%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.45×
Current ratio
2.92×
Quick ratio
2.66×
Cash ratio
0.19×
Cash flow
Price / cash flow
57.26×
Price / free cash flow
57.5×
Free cash flow
$59.71M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ARQT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$143.92M
$129.86M
$105.4M
$129.5M
$99.22M
$81.5M
$65.85M
$71.36M
Cost of revenue
$12.46M
$10.94M
$9.78M
$11.69M
$8.69M
$7.49M
$8.83M
$6.91M
Gross profit
$131.46M
$118.92M
$95.61M
$117.82M
$90.53M
$74.01M
$57.02M
$64.46M
Selling, general and administrative
$99.6M
$82.14M
$74.08M
$78.98M
$62.4M
$69.17M
$64M
$57.61M
Research and development
$22.42M
$20.36M
$30.63M
$20.45M
$19.6M
$19.45M
$17.54M
$14.48M
Total operating expenses
$122.02M
$102.49M
$104.7M
$99.43M
$82.01M
$88.62M
$81.55M
$72.09M
Operating income
$9.44M
$16.43M
-$9.09M
$18.39M
$8.53M
-$14.61M
-$24.53M
-$7.63M
Interest expense
-$2.96M
-$3.41M
-$4.37M
-$3M
-$3.07M
-$3.03M
-$2.98M
-$5.55M
Income before taxes
$9M
$15.15M
-$11.2M
$17.87M
$7.49M
-$15.54M
-$24.78M
-$10.47M
Income taxes
$195K
$136K
$93K
$470K
$80K
$342K
$279K
$323K
Net income
$8.8M
$15.01M
-$11.3M
$17.4M
$7.41M
-$15.89M
-$25.06M
-$10.79M
Net income attributable to common shareholders
$8.8M
$15.01M
-$11.3M
$17.4M
$7.41M
-$15.89M
-$25.06M
-$10.79M
EBITDA
$11.12M
$15.87M
-$8.53M
$14.28M
$12.63M
-$17.59M
-$21.55M
-$9.28M
Basic earnings per share
$0.07
$0.11
-$0.09
$0.14
$0.06
-$0.13
-$0.20
-$0.09
Diluted earnings per share
$0.06
$0.11
-$0.09
$0.14
$0.06
-$0.13
-$0.20
-$0.09
Recent news
Company coverage with links to the original publishers.
Arcutis Biotherapeutics announced the grant of 58,500 restricted stock units and options to purchase 17,000 shares to six newly hired employees as a material inducement for employment. The awards were granted under the 2022 Inducement Plan with an exercise price of $31.26 per share, reflecting the company's continued hiring and growth in its commercial-stage dermatology business.
Sarepta Therapeutics is expected to report Q3 2026 earnings of $0.37 per share (up 384.6% YoY) but with revenues declining 12.7% to $348.48 million. However, consensus EPS estimates have been revised 77.14% lower in the last 30 days, and the stock carries a Zacks Rank #5 with a negative Earnings ESP of -28.96%, making it an unlikely earnings-beat candidate.
Arcutis Biotherapeutics is expected to report Q3 2026 earnings on November 4, with consensus estimates of $0.17 EPS (up 183.3% YoY) and $141.64M revenue (up 42.8% YoY). The company has a positive Earnings ESP of +15.39% combined with a Zacks Rank #3, suggesting a likely earnings beat. The company has beaten consensus estimates in 3 of the last 4 quarters.
Arcutis Biotherapeutics announced the appointment of Dr. Rob Scott, a veteran pharma executive with over 40 years of experience, to its Board of Directors effective October 23, 2026. Dr. Scott, formerly Chief Medical Officer at AbbVie, brings extensive expertise in drug development and regulatory approvals. The company highlighted strong adoption of its ZORYVE product and a growing pipeline of new indications and novel biologics.
Arcutis Biotherapeutics announced it will report third quarter 2026 financial results and provide a business update on November 4, 2026, followed by a conference call at 4:30 p.m. ET. The commercial-stage biopharmaceutical company focuses on developing treatments for chronic inflammatory skin diseases.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.